Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients
Nuklearmedizin - NuclearMedicine · 01.06.2024 · 63 (03) · 199-206
DOI: 10.1055/a-2284-0593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2024. Verfasst von Felix Bock und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Radiation Oncology, Rostock University Medical Center, Rostock, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Gallium Radioisotopes, Gallium Isotopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
This study aimed to assess the impact of 68Ga-PSMA PET/CT on radiation treatment (RT) planning in prostate cancer patients with salvage (sRT) or definitive (dRT) radiotherapy.
Methods
38 patients (27 sRT, median PSA 0.79 ng/ml (range 0.06–12.1); 11 dRT, median PSA 4.35 ng/ml (range 1.55–55.5) underwent 68Ga-PSMA PET/CT before RT. Influence of 68Ga-PSMA PET/CT on the extent of planning target volume (PTV) and addition of PET-based boosts were assessed. Median follow up was 12 months (range 3–24).
Results
68Ga-PSMA PET/CT showed positive findings in 23/38 patients (8/23: local recurrence (LR), 11/23: nodal metastasis, 1/23: LR and nodal, 2/23: solitary bone metastasis, 1/23: oligometastatic nodal/ bone metastases). In sRT primary PTV was changed in 16/27 patients extending the PTV to the lymphatic drainage (10/16), PSMA-positive LR (3/16), bone metastases (2/16) and both nodal/bone metastases (1/16). PET-based increase of primary PTV was 116%. PET-based boosts were administered in 19/27 patients (8/19: local, 10/19: nodal, 1/19: both), median boost volume was 31.3 cm3 (range 17.2–80.2) (local) and 19.7 cm3 (range 3.0–109.3) (nodal). PTV was changed in 1/11 (9%) of dRT patients (extension of primary PTV to the lymphatic drainage (RT volume of 644.5 cm3), additional nodal boost (volume of 2.7 cm3, 23.1 Gy)). All patients showed biochemical response (mean PSA decrease 88.8 +/– 14.0%). Nadir PSA was reached 10 months (range 1–17) after end of RT (median 0.07 ng/ml, range 0.002–3.96). Within a median 12 months follow-up (range 3–22/8–24 in sRT/dRT), median PSA was 0.05 ng/ml (range 0.002–8.5) (sRT) and 0.26 ng/ml (range 0.02–2.68) (dRT).
Conclusions
68Ga-PSMA PET/CT influenced sRT planning in almost 63% and dRT in 9% of patients by change of PTV and additional boosts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy and Radiation Oncology, Rostock University Medical Center, Rostock, Germany.
- Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany.
Zitieren
APA
Bock, F., Frerker, B., Schubert, L., Rennau, H., Kurth, J., Krause, B. J., Hildebrandt, G., & Schwarzenböck, S. M. (2024). Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients. Nuklearmedizin - NuclearMedicine, 63(03), 199-206. https://doi.org/10.1055/a-2284-0593
Vancouver
Bock F, Frerker B, Schubert L, Rennau H, Kurth J, Krause BJ, et al. Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients. Nuklearmedizin - NuclearMedicine. 2024;63(03):199-206. doi:10.1055/a-2284-0593
BibTeX
@article{Bock2024,
author = {Bock, Felix and Frerker, Bernd and Schubert, Laura and Rennau, Hannes and Kurth, Jens and Krause, Bernd J and Hildebrandt, Guido and Schwarzenböck, Sarah Marie},
title = {Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2024},
volume = {63},
number = {03},
pages = {199--206},
doi = {10.1055/a-2284-0593}
}
EUVIMED